الفهرس 
B’l’IOLOGY, C:t.ASSIFICA’l’ION AND PA’l’HOGINESIS OF DIABETES MELLITUSOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
Glipizide {Hinidiab) is one of the new sulfonylurea
drugs. h’e studied its effect in two different dosage
schedules; a single morning dose: versus an equally divided
three doses before meals, in non-insulin dependent
diabetic patients (KIDDJ>i).
The absolute efficacy of glipizide in controlling
diabetes mellitus was satisfactory as regards fasting
serum glucose, Hb A
1c, serum cholesterol and serurn triglycerides.
However, it produced inadequate effect on
seru.u HDL-Cholesterol. More over, the imrnunoreacti ve
insulin was not significantly increased inspite of adequate
control of seru.u glucose levels which might be due
to extrapancreatic mechanisms.
There was no significant difference between the two
dosage schedules even between those patients who were
still insufficiently controlled. The maximum therapeutic
control was achieved after three months, either by single
or divided doses of glipizide beside the diet control.
In conclusion, glipizide can be used in the treatment
of NIDDM, either as single morning dose prior to breakfast
by 30 minutes or in equally divided doses before the three
meals. Glipizide, effects on the metabolic disturbances in
NID~1. are probably independent of the pattern of the dosage
used.